Chymase inhibition protects diabetic rats from renal lesions

Zhang,Mei; Huang,Wen; Bai,Jing; Nie,Xiaodong; Wang,Wen

doi:10.3892/mmr.2016.5234

Chymase inhibition protects diabetic rats from renal lesions

Authors:
- Mei Zhang
- Wen Huang
- Jing Bai
- Xiaodong Nie
- Wen Wang
View Affiliations

Affiliations: Department of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China
Published online on: May 10, 2016 https://doi.org/10.3892/mmr.2016.5234
Pages: 121-128
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of a chymase inhibitor on renal injury in diabetic rats. A total of 24 Sprague-Dawley rats were randomly divided into the following groups: The control group (n=7), the diabetes group (DM group; n=7), and the DM + chymase inhibitor group (DM + Chy‑I group; n=10). Diabetes was induced via an intraperitoneal injection of streptozotocin (65 mg/kg). Rats in the DM + Chy‑I group were administered 1 mg/kg chymase inhibitor [Suc-Val-Pro-PheP-(OPh)2] daily for 12 weeks by intraperitoneal injection. Subsequently, kidney weight, various biochemical parameters and blood pressure were measured. In addition, the expression levels of fibronectin (FN), type IV collagen (ColIV), transforming growth factor (TGF)‑β1 and vascular endothelial growth factor (VEGF) were determined by immunohistochemistry and reverse transcription polymerase chain reaction. Compared with in the DM group, the levels of serum cholesterol and urinary albumin/creatinine were decreased in the DM + Chy‑I group (P<0.05). Furthermore, chymase inhibition reduced the overexpression of FN, ColIV, TGF‑β1 and VEGF (P<0.05) in the renal tissue of diabetic rats. These results indicated that chymase inhibition may reduce the excretion of urinary albumin and the deposition of extracellular matrix components in the kidney of diabetic rats. These effects may be mediated by altered expression of the VEGF and TGF‑β1 pathways. In conclusion, chymase inhibition may be considered a potential method for the treatment of renal damage.

View Figures

View References

1	Huang XR, Chen WY, Truong LD and Lan HY: Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 14:1738–1747. 2003. View Article : Google Scholar : PubMed/NCBI
2	Fan YY, Nishiyama A, Fujisawa Y, Kobori H, Nakano D, Matsuura J, Hase N, Hitomi H, Kiyomoto H, Urata H and Kohno M: Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J Pharmacol Sci. 111:82–90. 2009. View Article : Google Scholar : PubMed/NCBI
3	Urata H, Kinoshita A, Misono KS, Bumpus FM and Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 265:22348–22357. 1990.PubMed/NCBI
4	Miyazaki M and Takai S: Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 100:391–397. 2006. View Article : Google Scholar : PubMed/NCBI
5	Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y and Miyazaki M: A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)] 2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther. 304:841–844. 2003. View Article : Google Scholar : PubMed/NCBI
6	Okamoto Y, Takai S and Miyazaki M: Effect of chymase-dependent transforming growth factor beta on peritoneal adhesion formation in a rat model. Surg Today. 34:865–867. 2004. View Article : Google Scholar : PubMed/NCBI
7	Oleksyszyn J and Powers JC: Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl) phosphonate diphenyl esters. Biochemistry. 30:485–493. 1991. View Article : Google Scholar : PubMed/NCBI
8	Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S and Miyazaki M: Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 467:141–144. 2000. View Article : Google Scholar : PubMed/NCBI
9	Ninichuk V, Khandoga AG, Segerer S, Loetscher P, Schlapbach A, Revesz L, Feifel R, Khandoga A, Krombach F, Nelson PJ, et al: The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol. 170:1267–1276. 2007. View Article : Google Scholar : PubMed/NCBI
10	Cristovam PC, Carmona AK, Arnoni CP, Maquigussa E, Pereira LG and Boim MA: Role of chymase in diabetic nephrology. Exp Biol Med (Maywood). 237:985–992. 2012. View Article : Google Scholar
11	Uehara Y, Urata H, Ideishi M, Arakawa K and Saku K: Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 55:870–876. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kovanen PT: Mast cells: Multipotent local effector cells in atherothrombosis. Immunol Rev. 217:105–122. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ruiz-Torres MP, López-Ongil S, Griera M, Díez-Marqués ML, Rodríguez-Puyol M and Rodríguez-Puyol D: The accumulation of extracellular matrix in the kidney: Consequences on cellular function. J Nephrol. 18:334–340. 2005.PubMed/NCBI
14	Leskinen MJ, Lindstedt KA, Wang Y and Kovanen PT: Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol. 23:238–243. 2003. View Article : Google Scholar : PubMed/NCBI
15	Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, Ikeda T and Komeda M: Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 29:57–64. 2006. View Article : Google Scholar : PubMed/NCBI
16	Maeda Y, Inoguchi T, Takei R, Sawada F, Sasaki S, Fujii M, Kobayashi K, Urata H, Nishiyama A and Takayanagi R: Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol. 299:F1328–F1338. 2010. View Article : Google Scholar : PubMed/NCBI
17	Simon M, Röckl W, Hornig C, Gröne EF, Theis H, Weich HA, Fuchs E, Yayon A and Gröne HJ: Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: Localization and [125I]VEGF binding sites. J Am Soc Nephrol. 9:1032–1044. 1998.PubMed/NCBI
18	Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, et al: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 12:1434–1447. 2001.PubMed/NCBI
19	Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K and Koike T: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 42:579–588. 1999. View Article : Google Scholar : PubMed/NCBI
20	Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK and Won NH: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl. 77:S104–S112. 2000. View Article : Google Scholar : PubMed/NCBI
21	de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W and Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 12:993–1000. 2001.PubMed/NCBI
22	Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH and De Vriese AS: A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant. 21:324–329. 2006. View Article : Google Scholar
23	Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ and Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 48:2229–2239. 1999. View Article : Google Scholar : PubMed/NCBI
24	Hovind P, Tarnow L, Oestergaard PB and Parving HH: Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl. 75:S56–S61. 2000. View Article : Google Scholar : PubMed/NCBI
25	Katada J, Muramatsu M, Hayashi I, Tsutsumi M, Konishi Y and Majima M: Significance of vascular endothelial cell growth factor upregulation mediated via a chymase-angiotensin-dependent pathway during angiogenesis in hamster sponge granulomas. J Pharmacol Exp Ther. 302:949–956. 2002. View Article : Google Scholar : PubMed/NCBI
26	Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH and Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 111:707–716. 2003. View Article : Google Scholar : PubMed/NCBI
27	Wang L, Kwak JH, Kim SI, He Y and Choi ME: Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem. 279:33213–33219. 2004. View Article : Google Scholar : PubMed/NCBI
28	Li X, Hu J, Zhang Q, Sun X and Li S: Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta 1 and VEGF. Br J Pharmacol. 157:994–1003. 2009. View Article : Google Scholar : PubMed/NCBI
29	Takai S, Jin D and Miyazaki M: Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci. 118:311–316. 2012. View Article : Google Scholar : PubMed/NCBI
30	Khera TK, Martin J, Riley SG, Steadman R and Phillips AO: Glucose modulates handling of apoptotic cells by mesangial cells: Involvement of TGF-beta1. Lab Invest. 87:690–701. 2007. View Article : Google Scholar : PubMed/NCBI
31	Umezono T, Toyoda M, Kato M, Miyauchi M, Kimura M, Maruyama M, Honma M, Yagame M and Suzuki D: Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy. J Nephrol. 19:751–757. 2006.PubMed/NCBI
32	Grande JP, Warner GM, Walker HJ, Yusufi AN, Cheng J, Gray CE, Kopp JB and Nath KA: TGF-beta1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production. Exp Biol Med (Maywood). 227:171–181. 2002.
33	Shankland SJ, Scholey JW, Ly H and Thai K: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int. 46:430–442. 1994. View Article : Google Scholar : PubMed/NCBI
34	Geng H, Lan R, Wang G, Siddiqi AR, Naski MC, Brooks AI, Barnes JL, Saikumar P, Weinberg JM and Venkatachalam MA: Inhibition of autoregulated TGF-beta signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia. Am J Pathol. 174:1291–1308. 2009. View Article : Google Scholar : PubMed/NCBI